Status:

UNKNOWN

SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant Schizophrenia

Lead Sponsor:

Shanghai Mental Health Center

Conditions:

Treatment-resistant Schizophrenia

Eligibility:

All Genders

18-55 years

Phase:

PHASE3

Brief Summary

The project intends to take treatment-resistant schizophrenia as the research object and uses sequential multiple assignment randomized trial(SMART) design to define the treatment recommendations of d...

Detailed Description

This trial is a sequential multiple-assignment RCT design of antipsychotic drugs, planning to recruit 162 people with treatment-resistant schizophrenia followed for 12 months. The study includes three...

Eligibility Criteria

Inclusion

  • meet the DSM-5 diagnostic criteria for schizophrenia,
  • be 18-55 years of age,
  • treatment-resistant schizophrenia:no response to sufficient doses (400-600 mg/ day CPZ equivalent) of at least two antipsychotics in the past 5 years,
  • Informed consent.

Exclusion

  • Patients with medical or psychiatric comorbidities and those who require concomitant other medications are excluded.
  • Patients with contraindications to even one of the proposed treatment arms are excluded.
  • Patients with risks such as extreme agitation, stupor or suicide are excluded.
  • Female patients with pregnancy or breast-feeding are also excluded.

Key Trial Info

Start Date :

December 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2022

Estimated Enrollment :

162 Patients enrolled

Trial Details

Trial ID

NCT04528095

Start Date

December 1 2020

End Date

December 1 2022

Last Update

August 27 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China, 200030